Home » Newsletters » BioWorld Asia

BioWorld Asia

June 2, 1999

View Archived Issues

Cortecs' Macritonin Fails; Stock Drops One-Fourth

Dolly's Shorter Telomeres Mean Brief Culture Time Best In Therapy Research

RPR's p53 Gene Therapy Strong In Phase II Trials

CGL's Surface-Protein Work Boosted By #4M Financing

Genset, Alghne Sign Deal For Alzheimer's Research

AnorMED's HIV Treatment Moves Into Phase II Study

Thallia Plans Launch Of Circulatory Product

CAT Ending Program For Obesity Antibody

Appligene Oncor Says Sales Up, Losses Lower

Oxagen, Lynx Partnering In Disease-Linked SNPs

Cerep Reports Revenues, Enters Deal With Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...